Evidence map›Paper›PMID 31848230›Full record

ArticleNeurology(R) neuroimmunology & neuroinflammation2020

Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis.

Nuria Sola-Valls, Helena Ariño, Domingo Escudero, Elisabeth Solana, Albert Lladó, Raquel Sánchez-Valle, Yolanda Blanco, Albert Saiz, Josep Dalmau, Francesc Graus

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology(R) neuroimmunology & neuroinflammation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 4 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Recent advances in autoimmune encephalitis.Arquivos de neuro-psiquiatria · 2024
    Review
  14. Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  15. Outcome and Sequelae of Autoimmune Encephalitis.Journal of clinical neurology (Seoul, Korea) · 2024
    Review
  16. Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review.Neurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  17. Article
  18. Article
  19. Review
  20. Neuropsychological Performance in Autoimmune Limbic Encephalitis: Evidence from an Immunotherapy-Naïve Cohort.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Nuria Sola-VallsFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Helena AriñoFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Domingo EscuderoFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Elisabeth SolanaFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Albert LladóFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Raquel Sánchez-ValleFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Yolanda BlancoFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Albert SaizFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Josep DalmauFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain.
Francesc GrausFrom the Neuroimmunology Program (N.S.-V., H.A., E.S., A.S., J.D., F.G.), Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Hospital Clinic; Neuroimmunology Unit (N.S.-V., D.E., Y.B., A.S.), Service of Neurology, Hospital Clinic, University of Barcelona; Alzheimer's Disease and Other Cognitive Disorders Unit (A.L., R.S.-V.), Service of Neurology, Hospital Clínic; Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), University of Barcelona, Spain; Department of Neurology (J.D.), University of Pennsylvania, PA; and Institució Catalana de Recerca i Estudis Avançats (ICREA) (J.D.), Barcelona, Spain. francesc.graus@idibaps.org.
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESUniversity of Pennsylvania · USUniversitat de Barcelona · ES

Funding

Paraneoplastic Disorders of the CNS: Autoantigen ProfilingR01NS077851 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI DALMAU, JOSEP O. · 2011 to 2015
$1.9M
NINDS NIH HHS R01 NS077851
6 · The paper itself

Abstract

objectiveTo assess the feasibility of a structured telephone interview examining the long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 (LGI1) encephalitis.

methodsTelephone interviews were conducted with 37 patients after a median follow-up of 87 months from disease onset and 23 healthy controls matched for age and sex. Cognitive status was assessed with the telephone Mini-Mental State Examination (t-MMSE) and 3 tests exploring verbal memory, fluency, and executive function. Functional status was evaluated with the Functional Activities Questionnaire and the modified Rankin Scale (mRS). Patients were classified as normal, with mild cognitive impairment (MCI), or with dementia based on cognitive and functional status. Assessment of the cognitive reserve was performed with a structured questionnaire. Logistic regression analysis was applied to identify predictors of cognitive impairment.

resultsTelephone interviews were successful in 36/37 (97%) patients. Cognitive impairment was detected in 27 (75%) including 17 with MCI and 10 with dementia. Eight (29%) patients would have been misclassified using only the t-MMSE. Twenty-six (72%) patients were functionally independent according to the mRS, but only 9 (35%) were cognitively normal. Independent predictors for long-term cognitive impairment were a low cognitive reserve (OR = 1.36, 95% CI: 1.05-1.76;

conclusionsTelemedicine is a feasible tool to assess the cognitive and functional outcome in patients with anti-LGI1 encephalitis. Cognitive impairment is often missed if only functional scales are used. Premorbid cognitive reserve and MRI with bilateral hippocampal hyperintensity were predictors for long-term cognitive impairment.

Indexed as

Cognitive ReserveFunctional StatusTelemedicineAgedAged, 80 and overCognitive DysfunctionDementiaEncephalitisFeasibility StudiesFemaleFollow-Up StudiesHumansInterview, PsychologicalIntracellular Signaling Peptides and ProteinsMaleMental Status and Dementia TestsIntracellular Signaling Peptides and ProteinsLGI1 protein, human

Identifiers

PMID31848230
PMCPMC6943366
OpenAlexW2996205080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.